You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

127 search results for: expert insights

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Dermatology
Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.
View more
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis
expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Dermatology
Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.
View more
Can Early Intervention Shape the Course of Atopic Dermatitis?
expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

Dermatology
Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.
View more
Factors Associated With Development of Atopic Comorbidities in AD
expert video

Factors Associated With Development of Atopic Comorbidities in AD

Dermatology
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
View more
Most Children With Atopic Dermatitis Have Uncontrolled Disease
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

Dermatology
Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.
View more
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.
View more
Most Burdensome Symptoms Rated by PN Patients
expert video

Most Burdensome Symptoms Rated by PN Patients

Dermatology
Dr. Chovatiya discusses the impact of pruritus on patients with PN.
View more
The Risks of Associated Systemic and Atopic Comorbidities with AD
expert video

The Risks of Associated Systemic and Atopic Comorbidities with AD

Dermatology
Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.
View more
When is the right time to consider a biologic in patients with CRSwNP?
expert video

When is the right time to consider a biologic in patients with CRSwNP?

Rhinology
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
View more
Association of Younger Age of Onset With Persistence of AD
expert video

Association of Younger Age of Onset With Persistence of AD

Dermatology
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
View more
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Rhinology
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: RomaniaChange country/region